XML 35 R20.htm IDEA: XBRL DOCUMENT
v3.8.0.1

Market Segments, Geographic Information and Significant Customers Market Segments, Geographic Information and Significant Customers (Notes) | 12 Months Ended
--- | ---
Dec. 31, 2017
Segment Reporting [Abstract] |
Information by Geographic Area and Customer Concentration [Text Block] | PRODUCT LINES, GEOGRAPHIC INFORMATION AND SIGNIFICANT CUSTOMERS Our primary product lines are Infusion Consumables, IV Solutions, Infusion Systems and Critical Care. The following table sets forth for the periods indicated, total revenue by product line as a percentage of total revenue:
|  | Year Ended December 31,
Product line |  | 2017 | 2016 | 2015
Infusion Consumables |  | 28 | % | 86 | % | 84 | %
IV Solutions |  | 40 | % | — | % | — | %
Infusion Systems |  | 23 | % | — | % | — | %
Critical Care |  | 4 | % | 14 | % | 16 | %
Other |  | 5 | % | — | % | — | %
|  | 100 | % | 100 | % | 100 | %
We sell products worldwide, on credit terms on an unsecured basis, as an OEM supplier, to independent medical supply distributors and directly to the end customer. The manufacturers and distributors, in turn, sell our products to healthcare providers. For the years ended December 31, 2016 and 2015, we had worldwide sales to one manufacturer, Pfizer, of 30% and 36%, respectively, of consolidated revenue and as of December 31, 2016, accounts receivable from Pfizer was 23% of consolidated accounts receivable. In February 2017, we completed the acquisition of Pfizer's HIS business, which we acquired in part to protect against the significant earnings exposure indicated above (see Note 2: Acquisitions and Strategic Transaction Expenses). We report revenue on a “where-sold” basis, which reflects the revenue within the country or region in which the ultimate sale is made to our external customer. The table below presents total company revenues, by major country or region (in thousands):
| As of December 31,
| 2017 |  | 2016 |  | 2015
Europe | $ | 100,423 |  |  | $ | 50,105 |  |  | $ | 45,062 |
Canada | 69,753 |  |  | 16,266 |  |  | 12,494 |
LATAM | 57,851 |  |  | 29,920 |  |  | 27,780 |
APAC | 54,465 |  |  | 10,304 |  |  | 7,047 |
Other | 30,184 |  |  | 11,083 |  |  | 10,622 |
Total foreign | $ | 312,676 |  |  | $ | 117,678 |  |  | $ | 103,005 |
United States | 979,937 |  |  | 261,694 |  |  | 238,663 |
Worldwide total | $ | 1,292,613 |  |  | $ | 379,372 |  |  | $ | 341,668 |
Domestic sales accounted for 76%, 70% and 71% of total revenue in 2017, 2016 and 2015, respectively. International sales accounted for 24%, 30% and 29% of total revenue in 2017, 2016 and 2015, respectively. The table below presents our gross long-lived assets, consisting of property, plant and equipment, by country or region (in thousands):
|  | As of December 31,
|  | 2017 |  | 2016
Costa Rica |  | $ | 80,956 |  |  | $ | — |
Mexico |  | 61,008 |  |  | 57,971 |
Other LATAM |  | 19,432 |  |  | — |
Canada |  | 4,362 |  |  | — |
Italy |  | 6,860 |  |  | 4,320 |
Spain |  | 5,601 |  |  | — |
Other Europe |  | 2,625 |  |  | 966 |
APAC |  | 5,169 |  |  | 41 |
Total foreign |  | $ | 186,013 |  |  | $ | 63,298 |
United States |  | 422,810 |  |  | 180,657 |
Worldwide total |  | $ | 608,823 |  |  | $ | 243,955 |

X
- Definition Information by Geographic Area and Customer Concentration [Text Block] + References No definition available. + Details
Name: | icui_InformationbyGeographicAreaandCustomerConcentrationTextBlock
Namespace Prefix: | icui_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration